RECRUITINGPhase 1 / Phase 2INTERVENTIONAL

Feasibility of Semaglutide in Advanced Lung Disease

Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study

About This Trial

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension - Age \> 18 - BMI \> 30 kg/m2 - Requires supplemental oxygen on exertion - Stable treatment regimen X 90 days - Use of disease-modifying therapy Who Should NOT Join This Trial: - Diabetes - Pregnant or Breastfeeding - Recent weight loss - Recent or chronic GI complaints - History of gastroparesis - History of scleroderma - Hospitalized at time of evaluation - Use of weight loss medication in last 90 days - Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2) - Uncontrolled thyroid disease - History of acute/chronic pancreatitis - Prior suicide attempt - Suicidal ideation in last 90 days - Presence of a pacemaker or defibrillator Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension * Age \> 18 * BMI \> 30 kg/m2 * Requires supplemental oxygen on exertion * Stable treatment regimen X 90 days * Use of disease-modifying therapy Exclusion Criteria: * Diabetes * Pregnant or Breastfeeding * Recent weight loss * Recent or chronic GI complaints * History of gastroparesis * History of scleroderma * Hospitalized at time of evaluation * Use of weight loss medication in last 90 days * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2) * Uncontrolled thyroid disease * History of acute/chronic pancreatitis * Prior suicide attempt * Suicidal ideation in last 90 days * Presence of a pacemaker or defibrillator

Treatments Being Tested

DRUG

Semaglutide Pen Injector

Once weekly subcutaneous injection

Locations (1)

University of Pennsylvania Perelman School of Medicine

Philadelphia, Pennsylvania, United States